NeuroBionics, a neurotech company revolutionising neuromodulation therapy with minimally invasive implantable devices, today announced the successful close of its $5 million Seed Round. The round was led by Dolby Family Ventures with Future Ventures, GreyMatter Capital, Focalpoint Partners, Lionheart Ventures, Jumpspace Ventures, and Dr. Thomas Insel, former Director of the National Institute of Mental Health.
The funding will enable NeuroBionics to accelerate the development of its cutting-edge endovascular neuromodulation platform. Building upon over a decade of innovation at the Massachusetts Institute of Technology, NeuroBionics aims to expand access to neuromodulation therapies for millions of patients with neurological disorders through a minimally invasive approach to neuromodulation.
Related: Neko Health raises $260m for healthcare scanner advancement
Leveraging endovascular techniques to deploy a hair-thin device within blood vessels and deliver neuromodulation therapy, NeuroBionics aims to eliminate invasive, open surgical approaches necessary to implant today’s neuromodulation devices. This transformative technology has the potential to redefine the treatment landscape, offering safer, more accessible, and effective therapeutic options for patients worldwide.
“NeuroBionics’ approach to neuromodulation has the potential to dramatically improve patient outcomes by increasing safety, precision, and accessibility,” said David Dolby, CEO of Dolby Family Ventures. “Their flexible neuronal interface fibers and endovascular delivery system represent a transformative leap in bioelectronic medicine, and we are excited to support the team as they advance toward clinical validation.”
“NeuroBionics is pioneering a revolutionary technology that will transform how we treat complex neurological disorders. Their endovascular platform tackles the critical need for more accessible, effective therapies.” added Steve Jurvetson, Co-Founder at Future Ventures. “Future Ventures is excited to join this journey to bring this groundbreaking technology to patients worldwide.”
“We are thrilled to work alongside this exceptional group of investors who share our excitement for redefining the future of neuromodulation,” said MJ Antonini, CEO and co-founder of NeuroBionics. “This funding milestone underscores the significant interest and confidence in our innovative approach, and the need for less-invasive solutions to expand access to neuromodulation therapies. We are now one step closer to delivering life-changing solutions to patients worldwide.”
The funds will support the company’s next phase of growth, including the development of its first clinical product, preclinical safety and efficacy validation, and the expansion of its world-class team of engineers and neuroscientists.
